ライフサイエンスコーパス: pegylated

1 lated 4 showed some improvements over the un-PEGylated (18)F-FBA-A20FMDV2 (1), it was the bi-terminal

2 odification with polyethylene glycol to form PEGylated (198)Au-GNPs.

3 PEGylated (2 KDa) lipids were modified with gentamicin (

4 Although the C-terminally PEGylated 4 showed some improvements over the un-PEGylat

5 F-FBA-A20FMDV2 (1), it was the bi-terminally PEGylated 5 that displayed the more favorable combinatio

6 higher for PEG(6)-DM1 ADCs than for the non-PEGylated ADC in the following order: (111)In-nimotuzuma

7 e toxicity and in determining dosing rate of PEGylated ADCs.

8 urthermore, treatment of wild-type mice with pegylated adenosine deaminase or CD73 antibodies also si

9 The efficacy of pegylated ADI (ADI-PEG20) in relapsed/refractory/poor-ri

10 PEGylated Ag(2)S superdots enable deep-tissue in vivo im

11 Biodistribution of the PEGylated agent shows observable fluorescence in xenogra

12 Here, we demonstrate that a long-acting, pegylated analog of the NT peptide (P-NT) reduces food i

13 The PEGylated analogues feature comparatively high log D(7.4

14 ulations of various PAs, (ii) development of PEGylated and targeted liposomal PAs, (iii) physico-chem

15 A (89)Zr-labeled PEGylated anti-CD8 VHH detected thymus and secondary lym

16 he factors that affect the residence time of PEGylated antibody fragments in the lungs following pulm

17 observed for a surface prepared with a thiol PEGylated aptamer HS-(CH(2))(6)-OP(O)(2)O-(CH(2)CH(2)O)(

18 effect of plasma arginine deprivation using pegylated arginine deiminase (ADI-PEG 20) against primar

19 Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essen

20 targetable by the arginine-degrading enzyme pegylated arginine deiminase (ADI-PEG 20).

21 The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not been ev

22 The Arg-degrading recombinant protein, pegylated arginine deiminase (ADI-PEG20), has been in cl

23 hanced the efficacy of arginine deprivation (pegylated arginine deiminase) and chemotherapy (cisplati

24 d patients to continuous versus intermittent pegylated-asparaginase (PEG-asp) treatment, hypothesizin

25 tion and clearance profiles of virtually any PEGylated biomacromolecule from biological fluid samples

26 The study identified a nanomolar potent PEGylated bis-sulfonamide CA inhibitor (25) able to sign

27 lipid nanoparticle (DLNP) system containing PEGylated BODIPY dyes (PBD) for mRNA delivery and near-i

28 ytosis pathways and biological activities of PEGylated BP nanosheets in cancer cells are revealed for

29 nse combined therapy strategy is achieved by PEGylated BP nanosheets, showing a promising and enhance

30 uantify the blood clearance of (13)C-PEG and PEGylated-BSA (bovine serum albumin) following their int

31 en atom transfer (1,5-HAT) in the decay of a PEGylated carbazyl (aminyl) radical in solution.

32 Here, we have shown that administration of PEGylated CBS into the circulation of homocystinuria mod

33 RT for a metabolic disorder and suggest that PEGylated CBS should be further explored for use in pati

34 ysteine and the normalization of cysteine in PEGylated CBS-treated model mice were accompanied by imp

35 High levels of uptake of PEGylated-CH1055 dye were observed in brain tumours in m

36 Herein we describe a PEGylated colistin prodrug whereby the PEG is attached v

37 ounts and ratios of core-forming polymers to PEGylated corona-forming polymers.

38 were tested as core-forming units, and both PEGylated, diblock polymers were screened as corona-form

39 It is found that PEGylated DNA experiences two opposing effects: local ex

40 The human-derived protein corona formed onto PEGylated doxorubicin-encapsulated liposomes (Caelyx) is

41 PEG) and PEGylated molecules is critical for PEGylated drug development.

42 nosis, image-guided surgery, and theranostic PEGylated drug therapies.

43 col (PEG) can lead to the rapid clearance of PEGylated drugs and are associated with increased risk o

44 uals who have never undergone treatment with PEGylated drugs but most likely have been exposed to PEG

45 duction to ensure the safety and efficacy of PEGylated drugs in patients would be a valuable clinical

46 urvival did not improve likely, because this pegylated enzyme does not enter hepatocytes and does not

47 Pegylated Escherichia coli asparaginase (PEG-asparaginas

48 FR104 is a monovalent pegylated Fab' Ab, antagonist of CD28, under development

49 head assessment of FR104 (n=5), a selective pegylated Fab' antibody fragment antagonist of CD28 that

50 anisms involved in the prolonged presence of PEGylated Fab' in the airway lumen might include binding

51 Currently, the long-acting pegylated form (pegasparaginase) is the only Escherichia

52 Despite reduced immunogenicity of the pegylated form in comparison with native interferon (IFN

53 A PEGylated form of CBS provided long-term stability and,

54 In vitro, a PEGylated form of the peptide, named BNZ132-1-40, reduce

55 I) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue

56 ed ATG (2.5 mg/kg intravenously) followed by pegylated G-CSF (6 mg subcutaneously every 2 weeks for 6

57 tion 4-24 months) were randomized to ATG and pegylated G-CSF (ATG+G-CSF) (N = 17) or placebo (N = 8).

58 Low-dose antithymocyte globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF)

59 jects (N = 89) were randomized to 1) ATG and pegylated granulocyte colony-stimulating factor (GCSF),

60 f low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte CSF (G-CSF) would preserve beta ce

61 We find that PEGylated graphene oxide nanosheets (nGO-PEGs) stimulate

62 a new type of silver nanoparticle composite, PEGylated graphene quantum dot (GQD)-decorated Silver Na

63 d CO molecules from TBHP/Fe(CO)(5) co-loaded PEGylated HMONs without reliance on oxygen, which brings

64 The J-aggregates inside PEGylated HMSNs are stable for multiple weeks in buffer

65 Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) anal

66 BCT-100, a pegylated human recombinant arginase, leads to a rapid d

67 PEGylated-HVGGSSV could be used to target cancers that o

68 TLRs in HCV genotype 1 patients who received pegylated IFN (PEG-IFN) plus ribavirin (RBV) therapy.

69 nvestigated whether DAPK plays a role in the pegylated IFN-alpha (peg-IFN-alpha)-induced antiviral ac

70 rom localized inflammatory skin reactions at pegylated IFN-alpha injection sites, were analyzed for t

71 hepadnaviral cccDNA transcription.IMPORTANCE Pegylated IFN-alpha is the only therapeutic regimen that

72 with sequential treatment of Entecavior and PEGylated IFN-alpha were recruited.

73 atment naive patients, patients treated with PEGylated IFN-alpha, and patients with sequential treatm

74 ls with chronic HCV treated with combination pegylated IFN-alpha, ribavirin, and telaprevir/boceprevi

75 A subset of patients suffering from pegylated IFN-alpha-associated exanthemas displayed posi

76 Skin biopsies obtained from pegylated IFN-alpha-associated exanthemas, as well as fr

77 e cutaneous reactions has been reported with pegylated IFN-alpha.

78 We previously reported that pegylated IFN-alpha2a (Peg-IFN-alpha2a) added to antiret

79 to receive combination therapy with low-dose pegylated IFN-alpha2a.

80 rapeutic for influenza, as administration of pegylated IFN-lambda improves lung function and survival

81 athogenesis and supports the clinical use of pegylated IFN-lambda1a as a treatment for human COVID-19

82 observation correlated with the presence of pegylated IFN-specific T cells (3/11).

83 on with high CE and current density in these PEGylated IL media.

84 Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10

85 sed to characterize Mg(2+) speciation in the PEGylated ILs and BMPyrTFSI containing Mg(BH4)2 by study

86 the organic pyrrolidinium cation of the ILs (PEGylated ILs), were prepared that facilitate reversible

87 electrodeposition processes in two specific PEGylated-ILs were compared against that in the widely s

88 ation study, we used a next-generation, mono-pegylated interferon (IFN) alpha-2b isoform, ropeginterf

89 Pegylated interferon (IFN) has been used to treat chroni

90 hronically infected by HCV, and treated with pegylated interferon (IFN)/ribavirin or more-efficacious

91 efficacy and safety of sofosbuvir (SOF) plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in pa

92 5A-based therapy with daclatasvir (DCV) plus pegylated interferon (Peg-IFN) and ribavirin (RBV), with

93 type 1 (GT1) patients were administered with pegylated interferon (Peg-IFN) and/or ribavirin (RBV), w

94 r (SOF) plus ribavirin (RBV) with or without pegylated interferon (Peg-IFN) do not have established r

95 We investigated whether adding on pegylated interferon (Peg-IFN) to ETV therapy enhances s

96 used were: Sofosbuvir (SOF)/ribavirin (RBV)/pegylated interferon (PEG-IFN), 25.2%; SOF/RBV, 62.4%; S

97 The introduction of pegylated interferon (PEG-IFN)-alpha in the treatment of

98 ard, which included antiviral treatment with pegylated interferon (Peg-IFN)-based therapies as well a

99 y are associated with treatment responses to pegylated interferon (PEG-IFN)-based therapy in patients

100 tion limit of Western blot for low-abundance PEGylated interferon (Pegasys) and recombinant human CTL

101 with cirrhosis or previous null response to pegylated interferon (peginterferon) plus ribavirin (PR-

102 me was performed on 11 entecavir-treated and pegylated interferon (peginterferon)-treated patients.

103 best available therapy group), interferon or pegylated interferon (ten [13%] of 75), pipobroman (five

104 imeprevir +/- ribavirin (RBV), n = 53; SOF + pegylated interferon + RBV, n = 25; SOF + RBV, n = 36; a

105 Treatment-experienced (prior interferon or pegylated interferon +/- ribavirin or sofosbuvir plus ri

106 ving NA therapy and 86 patients treated with pegylated interferon alfa (Peg-IFN) and adefovir.

107 Pegylated interferon alfa (PEG-IFNalpha) is effective in

108 with tenofovir disoproxil fumarate (TDF) and pegylated interferon alfa-2a (pegIFN) in patients with c

109 V DNA load, >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks.

110 INTERPRETATION: Pegylated interferon alfa-2a can induce durable haematol

111 ssed the safety and efficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HB

112 Pegylated interferon alfa-2a induced haematological (66

113 Pegylated interferon alfa-2a is an immunomodulatory agen

114 ntravenous REP 2139 and 180 mug subcutaneous pegylated interferon alfa-2a once per week for 15 weeks,

115 for 15 weeks, then monotherapy with 180 mug pegylated interferon alfa-2a once per week for 33 weeks.

116 INTERPRETATION: Combined REP 2139 and pegylated interferon alfa-2a therapy is safe, well toler

117 The initial starting dose of pegylated interferon alfa-2a was 450 mug subcutaneously

118 ess than <1 IU/mL before the introduction of pegylated interferon alfa-2a.

119 This is not the case for pegylated interferon alpha (IFN-alpha)-induced neutropen

120 elopment of the NLEM decided to include both pegylated interferon alpha 2a and alpha 2b into the NLEM

121 (QALYs) comparing between the combination of pegylated interferon alpha 2a or alpha 2b and ribavirin

122 Therefore, this research determined whether pegylated interferon alpha 2a or alpha 2b plus ribavirin

123 HCV treatment with pegylated interferon alpha 2a or alpha 2b plus ribavirin

124 Pegylated interferon alpha 2a, alpha 2b and ribavirin ha

125 ceived different antiviral therapy regimens (pegylated interferon alpha 2b and ribavirin different do

126 e not introduced (ie, treatment is only with pegylated interferon and oral ribavirin) to investigate

127 Treatment with pegylated interferon and ribavirin (hazard ratio 0.78; 9

128 Anti-HCV therapy comprised pegylated interferon and ribavirin (PegIFN-RBV) plus one

129 Compared to treatment with pegylated interferon and ribavirin (PR), and a protease

130 A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were

131 contrast, the historical cohort treated with pegylated interferon and ribavirin experienced only 10%

132 egimens and historical controls treated with pegylated interferon and ribavirin in a single health ca

133 who had failed treatment with >/= 4 weeks of pegylated interferon and ribavirin plus either boceprevi

134 ntified patients who had been treated with a pegylated interferon and ribavirin regimen (n = 4436) or

135 242 680), we identified those treated with a pegylated interferon and ribavirin regimen (PEG/RBV, n =

136 CI 21.8-25.3) in the group treated with the pegylated interferon and ribavirin regimen, 16.3 per 100

137 Randomisation was stratified by previous pegylated interferon and ribavirin treatment experience

138 (AGATE-I), treatment-naive and interferon or pegylated interferon and ribavirin treatment-experienced

139 s eradication, but conventional therapy with pegylated interferon and ribavirin yields approximately

140 nt threshold (67%; based on SVR reported for pegylated interferon and ribavirin) to achieve superiori

141 bavirin has been replaced by sofosbuvir plus pegylated interferon and ribavirin, and all-oral therapi

142 For genotype 6, sofosbuvir plus pegylated interferon and ribavirin, sofosbuvir plus ledi

143 reatment-naive or treatment-experienced with pegylated interferon and ribavirin.

144 tients who did not respond to treatment with pegylated interferon and ribavirin.

145 higher than historical controls treated with pegylated interferon and ribavirin; patients with glomer

146 tment-experienced) patients who had received pegylated interferon plus ribavirin all received the rib

147 Pegylated interferon plus ribavirin has been replaced by

148 s and implications in treatment responses to pegylated interferon plus ribavirin treatment (PegIFN/RB

149 HCV genotype 3 and cirrhosis who had failed pegylated interferon plus ribavirin, in 25 of 28 (89%) p

150 CV) treatment for children aged <12 years is pegylated interferon plus ribavirin.

151 eceive combination therapy with both NUC and pegylated interferon remain unsettled.

152 The current nucleos(t)ide analogue (NUC) and pegylated interferon therapies effectively help slow dis

153 - ribavirin or sofosbuvir plus ribavirin +/- pegylated interferon therapy) patients without cirrhosis

154 Investigators could add pegylated interferon to the regimen at their discretion.

155 /HCV dual-infected patients who had received pegylated interferon treatment were recruited.

156 ot responded to treatment with interferon or pegylated interferon with or without ribavirin, or sofos

157 e treatment experienced, whereas sofosbuvir, pegylated interferon, and ribavirin for 12 weeks is an a

158 t the maximum tolerated dose], interferon or pegylated interferon, pipobroman, anagrelide, approved i

159 therapy comprised hydroxyurea, interferon or pegylated interferon, pipobroman, anagrelide, approved i

160 ceived previous treatment with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combin

161 rt of 200 Egyptian CHC patients treated with Pegylated interferon-alpha (Peg-IFN) plus ribavirin.

162 considered difficult to treat in the era of pegylated interferon-alpha (Peg-IFN-alpha) and ribavirin

163 We studied the antiviral potency of pegylated interferon-alpha (pegIFNalpha) against HEV inf

164 genotype 1b infection and a null response to pegylated interferon-alpha and ribavirin who developed d

165 nosuppression or treatment with ribavirin or pegylated interferon-alpha can result in viral clearance

166 -boost regimen, with and without concomitant pegylated interferon-alpha/ribavirin therapy.

167 ith cirrhosis, and/or prior nonresponders to pegylated interferon-based regimens.

168 Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy.

169 or sofosbuvir plus ribavirin with or without pegylated interferon.

170 come of retreatment with SOF, ribavirin, and pegylated interferon.

171 retreatment outcome with SOF, ribavirin, and pegylated interferon.

172 th sofosbuvir and ribavirin, with or without pegylated interferon.

173 th sofosbuvir and ribavirin, with or without pegylated interferon.

174 kidney transplant, and 82% previously failed pegylated interferon/RBV-based regimens) received treatm

175 Daclatasvir and asunaprevir combined with pegylated interferon/ribavirin (peg-IFN/RBV) have shown

176 HCV genotype 1 patients receiving telaprevir/pegylated interferon/ribavirin in OPTIMIZE were analyzed

177 of care, sofosbuvir/simeprevir or sofosbuvir/pegylated interferon/ribavirin, was included for compari

178 evels in 15 patients treated with telaprevir/pegylated interferon/ribavirin.

179 irin, 87.0% in patients given sofosbuvir and pegylated-interferon plus ribavirin, and 70.6% of patien

180 stained virologic response (SVR) of 60% with pegylated-interferon/ribavirin.

181 ptions in association with administration of pegylated interferons were enrolled in the study (n = 22

182 ermal growth factor receptor (EGFR)-targeted pegylated LARLLT peptide and/or a glucose or biotin ethy

183 Here, we encapsulated cdGMP within PEGylated lipid nanoparticles (NP-cdGMP) to redirect thi

184 The SLN was made of unique PEGylated lipids and combination of the surfactants.

185 merging vesicles made from synthetic lipids (PEGylated lipids and POPC lipids) with native cell-membr

186 e results reveal the necessity of having the PEGylated lipids present during vesicle adsorption to pr

187 and 15) plus carboplatin (AUC 5, day 1) plus pegylated liposomal doxorubicin (30 mg/m(2), day 1) ever

188 e II inhibitors, doxorubicin, etoposide, and pegylated liposomal doxorubicin (PLD) in vivo, utilizing

189 Since pegylated liposomal doxorubicin (PLD) was the most preva

190 izumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacizuma

191 In advanced-stage KS, chemotherapy with pegylated liposomal doxorubicin or paclitaxel is the mos

192 ere randomly assigned to receive carboplatin-pegylated liposomal doxorubicin-bevacizumab (experimenta

193 Carboplatin-pegylated liposomal doxorubicin-bevacizumab is a new sta

194 active non-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin.

195 However, recent reports show that certain pegylated liposomal nanoparticles (PLNs) and polymeric n

196 Here, we demonstrate a novel PEGylated liposome system, named DAFODIL (Doxorubicin An

197 MM-302 is a HER2-targeted PEGylated liposome that encapsulates doxorubicin to faci

198 kinetics of doxorubicin (DOX), delivered by pegylated liposomes (PLD), to murine lung (3LL) and brea

199 n half-life of the 3HM was similar to 110-nm PEGylated liposomes (t1/2=15.5 and 16.5h, respectively),

200 APA, restoring the prolonged circulation of PEGylated liposomes and possibly other PEGylated therape

201 of prophylaxis with free PEG or tolerogenic PEGylated liposomes as a strategy to reduce the amount o

202 PEGylated liposomes containing paclitaxel were successfu

203 PEGylated liposomes have transformed chemotherapeutic us

204 tively restored the prolonged circulation of PEGylated liposomes in the presence of high titers of pr

205 posomal distribution in vivo by injection of pegylated liposomes radiolabeled with (111)In.

206 Gylated liposomes with short-circulating non-PEGylated liposomes showed much higher accumulation of P

207 liposomes showed much higher accumulation of PEGylated liposomes that persisted several days after th

208 atelets enabled the tPA-loaded, cRGD-coated, PEGylated liposomes to induce efficient fibrin clot lysi

209 ccumulation of DiR labeled, long-circulating PEGylated liposomes with short-circulating non-PEGylated

210 PEGylated liposomes with varying ratios of the targeting

211 n mice previously sensitized by injection of PEGylated liposomes, and free PEG did not elicit excess

212 in the plasmid DNA is encapsulated in 100 nm pegylated liposomes, which are targeted to organs with a

213 of APA induced by subsequently administered PEGylated liposomes.

214 than erythrocytes, and more selectively than PEGylated liposomes.

215 also showed higher silencing efficiency than PEGylated LYR-P and LER-P nanoparticles.

216 nding capacity of 293T/SL-alphaPEG cells for PEGylated macromolecules was higher than that of 293T/S-

217 Antibody drug conjugates (ADCs) with PEGylated-maytansine (PEG-DM1) show promise in vitro and

218 elop anti-PEG antibody during treatment with PEGylated medicines, suggesting that genetics might play

219 ive determination of the pharmacokinetics of PEGylated molecules can accelerate the process of drug d

220 okinetics of poly(ethylene glycol) (PEG) and PEGylated molecules is critical for PEGylated drug devel

221 nt tool for the quantification of a range of PEGylated molecules.

222 capacity method for quantifying free PEG and PEGylated molecules.

223 apacity and detection limit for free PEG and PEGylated molecules.

224 f PEGylation on MTX loading was observed but PEGylated MSNR (PMSNR) demonstrated increased MTX releas

225 predictions were verified experimentally and PEGylated nano-liposomal formulation of mupirocin (Nano-

226 ous injection of doxorubicin-free Doxil-like PEGylated nano-liposomes (Doxebo) prior to Doxil treatme

227 The increasing use in the last decade of PEGylated nanodrugs such as Doxil(R) has seen a rise in

228 omaterials but also suggest applications for PEGylated nanomaterials wherein immune stimulation is de

229 sts that polyethylene glycol-functionalized (PEGylated) nanomaterials are largely biocompatible and e

230 We prove for the first time that PEGylated nanoparticles evade major brain cell populatio

231 usly injected nanopharmaceuticals, including PEGylated nanoparticles, induce adverse cardiopulmonary

232 with 15-2b are more suitable for quantifying PEGylated nanoparticles.

233 lation and tissue biodistribution typical of PEGylated nanoparticles.

234 ung epithelial cells compared to uncoated or PEGylated-nanoparticles, and exhibit enhanced uniform di

235 Here we report the development of PEGylated-NHC ligands for Au-NP surfaces and the first e

236 Our PEGylated-NHC-Au-NPs are stable toward aggregation in aq

237 e lead formulation, DB4-PDB12, was optimally PEGylated not only to ensure colloidal stability (no cha

238 injury received an intravenous injection of PEGylated NP cocktail (20, 40, 100, and 500 nm, each wit

239 revealed that Abraxane, an FDA-approved non-PEGylated NP formulation used for cancer therapy, binds

240 We administered fluorescent, 100 nm PEGylated-NPs into the cisterna magna of healthy mice an

241 nstrate that glutaraldehyde cross-linking of PEGylated oligolysine-coated DNs extends survival by up

242 Previously, PEGylated oligolysines were found to protect DNs against

243 rs) compared to cisplatin in conventional un-PEGylated particles (median survival=40days), cisplatin

244 arance, pretargeting increased the amount of PEGylated particles binding to cells by around 2-fold or

245 ted the first comparative study of uptake of PEGylated particles by all the major (immune and non-imm

246 ce within the brain, the mode of handling of PEGylated particles by the resident immune cells of the

247 i-alpha(v)beta(3)) but not by A2780 (same as PEGylated particles).

248 of conjugated particles was evaluated versus PEGylated particles, and PNB conjugation demonstrated th

249 trated increased MTX release compared to non-PEGylated particles.

250 (>90% positive cells) than the most densely PEGylated particles.

251 to either non-targeted or actively targeted PEGylated particles.

252 urvivin siRNA encapsulated, GalNAc decorated PEGylated PLGA nanoconjugates (NCs) viz., GalNAc@PEG@siR

253 tability when formulated as dual-drug loaded PEGylated PLGA nanoparticles (EGCG/AA NPs).

254 icrobubble-mediated delivery of FDA-approved pegylated poly lactic-co-glycolic acid (PLGA) nanopartic

255 ed of nanostructured lipid carrier (NLC) and PEGylated poly(amidoamine) dendrimer (PEG-PAMAM).

256 er therapeutic carriers such as FDA approved pegylated poly(lactic-co-glycolic acid) nanoparticles (P

257 blend of polyaspartic acid (PAA) and heavily PEGylated polyaspartic acid (PAA-PEG), was highly stable

258 that end we have developed long-circulating, PEGylated, polymeric hydrogels using the Particle Replic

259 y higher sensitivity for quantification of a PEGylated protein (PegIntron) and multiarm PEG macromole

260 Rapamycin was conjugated to a PEGylated protein therapeutic via a cleavable disulfide

261 y reduced the titers of ADAs compared with a PEGylated protein.

262 vercome these shortcomings, and more than 10 PEGylated proteins have been brought to market.

263 tivity for free PEG, PEG-like molecules, and PEGylated proteins with detection at ng mL(-1) levels.

264 ication of free PEG, PEG-like molecules, and PEGylated proteins, whereas the 293T/3.3 cells combined

265 64.6 +/- 13.7%) interacted with administered PEGylated quantum dots, but splenic macrophages took up

266 The bi-PEGylated radiotracer 5 showed a greatly improved pharma

267 itro or therapeutic depletion of arginine by pegylated recombinant arginase BCT-100, significantly de

268 PEGylated recombinant human granulocyte colony stimulati

269 Pegylated recombinant human hyaluronidase (PEGPH20) degr

270 ied tumor gemcitabine levels with injectable PEGylated recombinant human hyaluronidase (PEGPH20) to t

271 nstrate further that systemic treatment with pegylated recombinant hyaluronidase (PEGPH20) depletes i

272 Clearance of PEGylated rFVIII, rFVIIIFc, and rVIII-SingleChain is sti

273 The prolonged presence of PEGylated rhDNase in lung airspaces appears ideal for it

274 onfocal microscopy confirmed the presence of PEGylated rhDNase in lung airspaces for at least 7 days.

275 s work aimed to study the fate of native and PEGylated rhDNase in the lungs and to elucidate their bi

276 ant elimination pathways for both native and PEGylated rhDNase.

277 rIFN-alpha, we investigated the outcomes of pegylated-rIFN-alpha2a (PEG) therapy in ET and PV patien

278 nsferrin receptor monoclonal antibody (OX26)-PEGylated Se nanoparticles (OX26-PEG-Se NPs) were design

279 ssion tomography (PET), using (89)Zr-labeled PEGylated single-domain antibody fragments (nanobodies o

280 We used (89)Zr-labeled PEGylated single-domain antibody fragments (VHHs) specif

281 1)H NMR spectroscopy can be used to quantify PEGylated species in complex biological fluids directly,

282 For the best dimer, which contained a pegylated squaraine core, we obtained a very high turn-o

283 The probe derived from the core-pegylated squaraine showed the highest specificity to th

284 The PEGylated Sub-A (Sub-A-mPEG) was further encapsulated by

285 o-glycolic acid) (PLGA) nanoparticles with a PEGylated surface decorated with two different arginine-

286 Although select PEGylated therapeutics can induce anti-PEG antibodies (A

287 Given the large number of PEGylated therapeutics that are either FDA-approved or i

288 o ameliorate the APA response to sensitizing PEGylated therapeutics.

289 several clinical reports examining different PEGylated therapeutics.

290 d risk of serious adverse events for several PEGylated therapeutics.

291 on of PEGylated liposomes and possibly other PEGylated therapeutics.

292 ng the immunogenicity of PEG and efficacy of PEGylated therapeutics.Some individuals develop antibodi

293 More importantly, pegylated TNT-b10 LLNs is stable for over four weeks and

294 The tPA-loaded liposomes were PEGylated to improve their stability, and surface coated

295 emically administering a potent, long-acting PEGylated TRAIL (TRAILPEG) is profoundly anti-rheumatic

296 -bearing mice with polyethylene glycolyated (PEGylated) type-I interferon-alpha2b reduces the express

297 d mice (C57BL/6J) were injected daily with a PEGylated UCN2 peptide (compound A) at 0.3 mg/kg subcuta

298 nistration of tolerogenic nanoparticles with pegylated uricase inhibited the formation of ADAs in mic

299 monstrate the efficacy of the brain-permeant PEGylated version of the anti-solTNF peptide, XPro1595,

300 We report the synthesis and kinetic study of PEGylated, water-soluble aminyl radical 2.